Practice Apoptosis: When Partners Retire
Kicking off the first in a series of podcasts, a noted healthcare consultant discusses how retirement can fracture a practice.
In today’s challenging environment, community oncology practices must devise new business models if they are to continue providing high quality care for patients while adequately compensating their physicians. Practices must also adapt to an environment in which professional-fee revenue plays an increasingly important role in reimbursing for care.
In short, busy community doctors need to create a sound business plan that complements the skills and needs of their partners. Building the right practice “chemistry” is tantamount to success. So, what happens when a partner, or two, decides to retire? In this podcast, noted healthcare consultant, Thomas A. Paivanas, discusses the realities, with the caveat, fortune favors a prepared mind.
Stay tuned for our next expert podcast: Martin Neltner talks about quality in cancer care, what it means to the busy practitioner as we move forward into our brave new world of healthcare…
Practice Apoptosis: When Partners Retire
Right mouse click and "Save As" to download
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
